AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02257580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: E-Aminocaproic acid
Description: E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
Study NCT03262363 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Curcumin/NFE2L2 A>G
Description: The administration will be orally and the patient will be instructed to take two capsules per day for one week, one in the morning 15 minutes before breakfast and another at night 15 minutes before dinner, accompanied by a cup of 240 mL of pure water. It will be indicated to continue with their usual medical treatment.
Study NCT03262363 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/NFE2L2 A>G
Description: The administration will be orally and the patient will be instructed to take two capsules for 24 weeks, one in the morning 15 minutes before breakfast and another in the evening 15 minutes before dinner, accompanied by a 240 mL cup of pure water. They will be advised to continue their usual medical treatment.
Study NCT02788500 — intervention group
Intervention type: OTHER
Intervention: Incidence of sports-related injuries and illnesses
Description: The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
Study NCT02766660 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: All groups were measured by optical coherence tomography.
Study NCT03623724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: blended Cognitive-behavioral Therapy
Description: The protocol includes ten face-to-face cognitive-behavioral sessions combined with nine online sessions based on Moodbuster self-help treatment, delivered over a period of 16 weeks. The Moodbuster includes 7 modules (introduction, psychoeducation, behavioral activation, cognitive restructuring, problem solving, exercise and relapse prevention), a calendar and the possibility of sending and receiving messages to and from therapist, respectively. The mobile phone application will be used to support the therapeutic sessions and register the ecological momentary assessments concerning mood, sleep quality, anxiety and other emotional states that will be collected in a daily basis before, during and after the treatment.
Study NCT03623724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-As-Usual
Description: The protocol consists in routine care that patients receive when they are diagnosed with major depression in primary care. We will not interfere with treatments delivered in TAU, but the intervention will be tracked (e.g., medication). The psychiatrist of our team will monitor possible medicine intake (stabilized throughout the trial).
Study NCT00843908 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tension Free Vaginal Tape
Description: Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
Study NCT00843908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miniarc
Description: The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
Study NCT03624257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: The participants in the laser group are treated by a combination of scaling and root planning (SRP) and 445 nm diode laser. The peri-implant pocket will be radiated with the 445 nm laser, removing bacteria, diseased epithelium and granulation tissue. The Power setting on the laser will be 0.7 W continuous wave and will be used at maximum 20 s Before cooling water is applied. Total treatment time will vary with the depth of the pocket and size of the surrounding bone crater.
Study NCT03624257 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mucosal flap surgery
Description: The participants will receive a conventional peri-implant mucosal flap surgery of affected implants, in combination with scaling and root planning (SRP), and return after 7-10 days for suture removal. The surgery is a well-established treatment of peri-implantitis.
Study NCT04158063 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual Task Training
Description: In total 12 Dual Task conditions will be performed in which 3 cognitive tasks are combined with 4 motor tasks:~Cognitive tasks:~* Titrated digit span backwards~* Auditory vigilance with alphabets~* Subtracting by 7~Motor tasks:~* Walking at self-selected speed~* Walking while carrying a cup of water~* Walking while stepping over obstacles~* Walking crisscross
Study NCT04158063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single Mobility Training
Description: standard routine training
Study NCT03064763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec
Description: Talimogene laherparepvec will be administered as an intralesional injection.
Study NCT01185353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01185353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered orally as background therapy
Study NCT01185353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Administered orally as background therapy
Study NCT01284491 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAK PlasmaBlade 4.0
Description: The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
Study NCT05172219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Sent Outreach with Embedded Asynchronous Care in Portal Message
Description: PCPs sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
Study NCT05172219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physician Sent Outreach without Embedded Asynchronous Care in Portal Message
Description: Physician sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
Study NCT01284491 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Electrosurgery with scalpel
Description: Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
Study NCT02212600 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: observational cohort of proximal humerus fractures
Study NCT01250444 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training
Description: Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
Study NCT00127270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darifenacin
Description: Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
Study NCT00127270 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Darifenacin
Description: Darifenacin tablets 7,5 mg or 15 mg once daily
Study NCT05172219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: System Sent Outreach with Embedded Asynchronous Care in Portal Message
Description: Health System sent a portal message encouraging a quit attempt embedded a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent.
Study NCT05172219 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: System Sent Outreach without Embedded Asynchronous Care in Portal Message
Description: Health System sent a portal message encouraging a quit attempt without a link to asynchronous care within a portal message encouraging a quit attempt in order to compare EMR-documented, physician-assisted quit attempts to those who received messages without the link 30 days after messages were sent. Half of the messages came from the patient's PCP and the other half came from the health system to determine if communication from a patient's physician was associated with more quit attempts.
Study NCT00127270 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral therapy
Description: Behavioral Modification Programme for symptoms of overactive bladder
Study NCT02102659 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Upper Limit Nutrition Support Therapy
Description: Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium
Study NCT02102659 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Formula Nutrition Support Therapy
Description: Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula.
Study NCT04267900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-HPArk2
Description: 99mTc-HPArk2 were injected into the patients before the SPECT/CT scans
Study NCT01978938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eravacycline
Study NCT01978938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Study NCT02184052 — intervention group
Intervention type: DRUG
Intervention: Meloxicam
Description: 7.5 mg or 15 mg
Study NCT04455490 — intervention group
Intervention type: OTHER
Intervention: Self-control
Description: We compared relevant scores of patients before and after surgery
Study NCT02032043 — intervention group
Intervention type: DRUG
Intervention: Annual versus Semiannual Albendazole plus Ivermectin MDA
Description: Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
Study NCT03552250 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Parenting for Lifelong Health for Young Children
Description: In this study, the 12 sessions-PLH version for parents of young children (2-9 years) will be delivered. The PLH (2 - 9) programme is delivered in groups of parents and includes the following general content 1) One-on-one time, 2) Say what you see, 3) Talking about feelings, 4) Praising and rewarding our children, 5) Giving positive, specific, and realistic instructions, 6) Establishing household rules and routines, 7) Redirecting negative behavior, 8) Ignoring negative attention seeking and demanding behavior, 9) Using consequences to support compliance, 10) Using Cool-down as a consequence for aggressive behavior, 11) Avoiding and resolving conflicts, 12) Reflection celebration, and moving on.
Study NCT04549883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theoretical practical educational session
Description: 1 Theoretical practical educational session of 15 Min about the importance of low back control during hip extension. Includes anatomical issues and one practical exercise in quadruped position
Study NCT02209428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
Study NCT02209428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
Study NCT02917018 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
Study NCT02004288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri Protectis DSM17938
Description: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
Study NCT02004288 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus reuteri Protectis DSM17938
Description: One chewable tablet with L. reuteri or placebo taken twice a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
Study NCT03154892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracameral injection
Description: Intracameral Conbercept injection for the treatment of NVG
Study NCT03154892 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal injection
Description: Intravitreal Conbercept injection for the treatment of NVG
Study NCT03353233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: Local anesthetic (numbing drug)
Study NCT03205254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: four days of participant-scaled isocaloric Mediterranean meals
Study NCT03353233 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block
Description: An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
Study NCT03205254 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fast food diet
Description: four days of participant-scaled isocaloric fast food meals
Study NCT03353233 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interspace Between the Popliteal Artery and Capsule of the Knee (iPACK) Block
Description: An ultrasound guided nerve block using a numbing medication called ropivacaine that numbs the nerves to the back of the knee.
Study NCT03353233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
Study NCT02285036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccination PPV23
Description: All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
Study NCT02285036 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: vaccination PNEUMOVAX 23
Description: Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
Study NCT01696682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Narrowed Gastric Conduit
Description: The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
Study NCT01696682 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Widened Gastric Conduit
Description: A widened gastric tube will be formed during the surgery
Study NCT03725462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardioskin
Description: Subjects have a monitoring with cardioskin and comparator
Study NCT03725462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuronaute
Description: Subjects have a monitoring with Neuronaute and comparator
Study NCT04024501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad ER8 capsule formulation (fasted)
Description: Each participant will receive single-dose treatment of 12 mg verinurad ER8 capsule with 240 mL water, following an overnight fast of at least 10 hours.
Study NCT04024501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad A-capsule formulation (fasted)
Description: Each participant will receive single-dose treatment of 12 mg verinurad A-capsule with 240 mL water, following an overnight fast of at least 10 hours.
Study NCT04024501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad A-capsule formulation (fed)
Description: Each participant will receive single dose treatment of 12 mg verinurad A-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
Study NCT04024501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad B-capsule formulation (fasted)
Description: Each participant will receive single-dose treatment of 12 mg verinurad B-capsule with 240 mL water, following an overnight fast of at least 10 hours.
Study NCT04024501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verinurad B-capsule formulation (fed)
Description: Each participant will receive single dose treatment of 12 mg verinurad B-capsule with 240 mL water, following a high-fat, high-calorie breakfast (after the overnight fast).
Study NCT01698957 — intervention group
Intervention type: OTHER
Intervention: Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.
Description: bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
Study NCT00388947 — intervention group
Intervention type: DEVICE
Intervention: AMS Prolapse Product
Description: AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
Study NCT03160560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClōSYS® Unflavored Rinse
Description: Subjects in Test group will receive ClōSYS® Unflavored Rinse.
Study NCT03160560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ClōSYS® Flavored Rinse
Description: Subjects in Test group will receive ClōSYS® Flavored Rinse.
Study NCT03160560 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in Placebo group will receive Placebo Rinse.
Study NCT03409822 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Masimo SpHb™ monitor
Description: Attach the Masimo Rainbow SET® Radical-7 ™ pulse oximeter probe to the third or fourth finger and perform a Masimo SpHb ™ monitor.
Study NCT03118440 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: zero-fluoroscopy 3D navigation
Description: Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
Study NCT03118440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional x-ray navigation
Description: Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
Study NCT00403260 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine - artesunate
Description: once a day for 3 days
Study NCT00403260 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mefloquine plus artesunate
Description: once a day for 3 days
Study NCT04574596 — intervention group
Intervention type: OTHER
Intervention: no Intervention
Description: This is an observational study. There is no intervention
Study NCT01431092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
Study NCT01431092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
Study NCT03581461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-Informed Mindfulness-Based Yoga
Description: The TIMBY program will involve twice weekly, 1-hour long sessions that will incorporate the central elements of Hatha Yoga - breathwork (pranayama), physical postures (asana) and meditation.
Study NCT03608150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Luminopia One
Description: Luminopia One is a virtual-reality based digital therapeutic that applies therapeutic modifications in real-time to cinematic content to rebalance visual input and treat amblyopia.
Study NCT03608150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Refractive Correction
Description: Standard of care refractive correction (ex. spectacles)
Study NCT02834845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane %2-3 for general anesthesia maintenance
Study NCT02834845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: Desflurane %6-8 for general anesthesia maintenance
Study NCT01090895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
Study NCT01090895 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.